Clinical trial

Course of Inflammation and Infection Markers in Critically Ill ICU Patients Under Casirivimab- and/or Tocilizumab Application

Name

University Ulm

Description

In a retrospective observational study, critically ill COVID-19 patients admitted to the ICU with the CoV-2 delta-variant between august 2021 and february 2022 were evaluated (ethics application nr. 129/22 of the ethics commssion of the university Ulm.

Trial arms

Trial start

2021-08-01

Estimated PCD

2022-04-28

Trial end

2023-12-31

Status

Completed

Treatment

treated without (N), with casirivimab / imdevimab (C) or tocilizumab (T), solely, or in combination of both (C + T)

IgG seronegative SARSCoV2-Spike antibody (\< 0,80 U/ml) COVID-19 patients were treated with 1 dose of subcutaneous casirivimab and imdevimab, 1200 mg (600 mg of each). Patients with CRP \> 75 mg/l or IL-6 \> 75 ng/l were treated with one dose of intravenous tocilizumab 8 mg/kg body weight

Arms:

C + T, treated with casirivimab / imdevimab and tocilizumab, C, treated with casirivimab / imdevimab, T, Treated with Tocilizumab

Other names:

casirivimab / imdevimab, tocilizumab

Size

Primary endpoint

Mortality rates in the 4 groups

28-day mortality

Eligibility criteria

Inclusion Criteria: * Clinical diagnosis of COVID-19 * CoV-2 delta-variant * critically ill patients * ICU Exclusion Criteria: * tuberculosis * active hepatitis * HIV

Protocol

{'studyType': 'OBSERVATIONAL', 'patientRegistry': False, 'designInfo': {'observationalModel': 'OTHER', 'timePerspective': 'RETROSPECTIVE'}, 'enrollmentInfo': {'count': 95, 'type': 'ACTUAL'}}

Updated at

2024-02-01

1 organization

1 product

6 indications

Organization

University of Ulm

Product

Treated without

Indication

COVID-19

Indication